6 assets in Giant Cell Glioblastoma

Therapeutic assets addressing Giant Cell Glioblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Giant Cell Glioblastoma	Case Comprehensive Cancer Center	P2	BBB (74)
Cediranib Giant Cell Glioblastoma	Lawrence Recht	P2	BBB (73)
Vorinostat Giant Cell Glioblastoma	National Cancer Institute (NCI)	P2	BB (68)
g207 Giant Cell Glioblastoma	Pediatric Brain Tumor Consortium	P2	CCC (53)
S-Gboxin Giant Cell Glioblastoma	Petrov, Andrey	P1	CC (43)
Cynk-001 Giant Cell Glioblastoma	Celularity Incorporated	P1/2	C (37)